Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Surgery Partners (NASDAQ:SGRY) and maintained a price target of $43.

August 20, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Surgery Partners, maintaining a price target of $43, indicating confidence in the stock's potential upside.
The reiteration of an Overweight rating and a maintained price target of $43 by a reputable analyst suggests a positive outlook for Surgery Partners. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100